ValuEngine upgraded shares of Innovus Pharmaceuticals (OTCMKTS:INNV) from a strong sell rating to a sell rating in a research report report published on Friday.

Separately, Zacks Investment Research raised Innovus Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 24th.

Innovus Pharmaceuticals (INNV) opened at $0.15 on Friday. Innovus Pharmaceuticals has a 12-month low of $0.08 and a 12-month high of $0.39. The firm has a market capitalization of $24.25, a PE ratio of -2.11 and a beta of 4.41.

Innovus Pharmaceuticals (OTCMKTS:INNV) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.01) earnings per share for the quarter. Innovus Pharmaceuticals had a negative return on equity of 330.39% and a negative net margin of 102.95%. The business had revenue of $2.22 million during the quarter. equities analysts anticipate that Innovus Pharmaceuticals will post -0.04 EPS for the current year.

WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2018/02/05/valuengine-upgrades-innovus-pharmaceuticals-innv-to-sell.html.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.